BRD2 and gonorrhea: Our results showed low MGMT expression (<50%) in 85.7% of PRL-secreting PAs, 90% of GH-secreting PAs, 81.5% of ACTH-secreting PAs, 93.3% of TSH-secreting PAs, 70.3% of FSH-secreting PAs and 94.3% of non-functioning PAs, predicting almost all subtypes of PAs are suitable for TMZ therapy, although only fewer curative cases were separately reported [[25],[26]].